Saskia A.J. Lesnik Oberstein

Leiden University Medical Center
Country flagNetherlands

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (13)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Background: A retrospective study has shown that EGFr (epidermal growth factor–like repeat) group in the NOTCH3 gene is an important cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) disease modifier of age at first stroke and white matter hyperintensity (WMH) volume. No study has yet assessed the effect of other known CADASIL modifiers, that is, cardiovascular risk factors and sex, in the context of NOTCH3 EGFr group. In this study, we determined the relative disease-modifying effects of NOTCH3 EGFr group, sex and cardiovascular risk factor on disease severity in the first genotype-driven, large prospective CADASIL cohort study, using a comprehensive battery of CADASIL clinical outcomes and neuroimaging markers. Methods: Patients with CADASIL participated in a single-center, prospective cohort study (DiViNAS [Disease Variability in NOTCH3 Associated Small Vessel Disease]) between 2017 and 2020. The study protocol included a clinical assessment, neuropsychological test battery and brain magnetic resonance imaging on a single research day. Multivariable linear, logistic and Cox regression models were used to cross-sectionally assess the effect of CADASIL modifiers on clinical severity (stroke, disability, processing speed) and neuroimaging markers (WMH volume, peak width of skeletonized mean diffusivity, lacune volume, brain volume, cerebral microbleed count). Results: Two hundred patients with CADASIL participated, of which 103 harbored a NOTCH3 EGFr 1–6 variant and 97 an EGFr 7–34 variant. NOTCH3 EGFr 1–6 group was the most important modifier of age at first stroke (hazard ratio, 2.45 [95% CI, 1.39–4.31]; P =0.002), lacune volume (odds ratio, 4.31 [95% CI, 2.31–8.04]; P =4.0×10 -6 ), WMH volume (B=0.81 [95% CI, 0.60–1.02]; P =1.1×10 -12 ), and peak width of skeletonized mean diffusivity (B=0.65 [95% CI, 0.44–0.87]; P =1.6×10 -8 ). EGFr 1–6 patients had a significantly higher WMH volume in the anterior temporal lobes and superior frontal gyri and a higher burden of enlarged perivascular spaces. After NOTCH3 EGFr group, male sex and hypertension were the next most important modifiers of clinical outcomes and neuroimaging markers. Conclusions: NOTCH3 EGFr group is the most important CADASIL disease modifier not only for age at first stroke and WMH volume but also strikingly so for a whole battery of clinically relevant disease measures such as lacune volume and peak width of skeletonized mean diffusivity. NOTCH3 EGFr group is followed in importance by sex, hypertension, diabetes, and smoking.

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2020

Collaborators (15)

Frank Baas

Professor of Genome Diagnostics

Leiden University

NETHERLANDS
View details

Francesca Del Gaudio

Karolinska Institutet

SWEDEN
View details

Minne Cerfontaine

Leiden University Medical Center

NETHERLANDS
View details

Ramin Zand

Pennsylvania State University

UNITED STATES
View details

Sam Neilson

University of Glasgow

UNITED KINGDOM
View details

Marco Duering

LMU University Hospital

UNITED STATES
View details

Raj N. Kalaria

-

UNITED KINGDOM
View details

Jeroen van der Grond

Leiden University Medical Center

NETHERLANDS
View details

Stéphanie Guey

INSERM

FRANCE
View details

Hyunjin Kim

Assistant professor

Asan Medical Center

SOUTH KOREA
View details

Martijn Malessy

Professor of Nerve Surgery

Leiden University

NETHERLANDS
View details

sailan wang

Karolinska Institutet

SWEDEN
View details

Kirsten Coupland

Karolinska Institutet

SWEDEN
View details

Justus L. Groen

-

NETHERLANDS
View details

Daniel Oliveira

Karolinska Institutet

SWEDEN
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.